Drug Patents owned by Am Regent

1. List of Injectafer drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11291645 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(8 months from now)

US11123321 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(8 months from now)

US9376505 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(8 months from now)

US7612109 AM REGENT Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
Feb, 2024

(1 year, 5 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478502 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

US11433091 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

US8895612 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

US7754702 AM REGENT Methods and compositions for administration of iron
Feb, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Apr 28, 2024
New Patient Population (NPP) Nov 19, 2024

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Method to treat ida in adults with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder weighing at least 40 kg by administering iv ferric carboxymaltose to give at least 0.6 g of iron in 15 minutes or less; Method to treat iron deficiency anemia in adults with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less; Method to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g of elemental iron in 15 minutes; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g of elemental iron in less than 15 minutes; Method to treat ida in adults & pediatric patients 1 year & older with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder by administering iv ferric carboxymaltose to give at least 0.7 g of iron in 15 minutes; Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 46.7 kg by administering iv ferric carboxymaltose to provide at least 0.7 g of elemental iron in < 15 minutes; Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex, with a substantially non-immunogenic carbohydrate component, in about 15 minutes or less.; Method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; Method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; Method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; Method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as ferric carboxymaltose in about 15 min or less; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering at least about 0.6 grams of iron as ferric carboxymaltose in about 15 minutes or less; Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex; Method of treating iron deficiency anemia in adults who have intolerance to or have had unsatisfactory response to oral iron associated with heavy uterine bleeding or a gastrointestinal disorder by intravenously administering ferric carboxymaltose; A method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron; A method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; Method of treating ida in adults & pediatric patients 1 yr & older having intolerance or unsatisfactory response to oral iron associated with heavy uterine bleeding or gastrointestinal disorder by intravenously administering ferric carboxymaltose; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron; Method of treating iron deficiency anemia in adult patients with non-dialysis dependent chronic kidney disease by intravenously administering ferric carboxymaltose; Method to treat iron deficiency anemia in adults & pediatric patients 1 year and older with intolerance or unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of INJECTAFER before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in